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Neuronal expression of major histocompatibility complex I (MHCI)-related molecules in 
adults and during CNS diseases is involved in the synaptic plasticity and axonal regen-
eration with mechanisms either dependent or independent of their immune functions. 
Motor neurons are highly responsive in triggering the expression of MHCI molecules 
during normal aging or following insults and diseases, and this has implications in the 
synaptic controls, axonal regeneration, and neuromuscular junction stability of these 
neurons. We recently reported that MHCI and immunoproteasome are strongly activated 
in spinal motor neurons and their peripheral motor axon in a mouse model of familial 
amyotrophic lateral sclerosis (ALS) during the course of the disease. This response was 
prominent in ALS mice with slower disease progression in which the axonal structure 
and function was better preserved than in fast-progressing mice. This review summa-
rizes and discusses our observations in the light of knowledge about the possible role 
of MHCI in motor neurons providing additional insight into the pathophysiology of ALS.
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iNTRODUCTiON
Amyotrophic lateral sclerosis (ALS) is an irreversible, fatal adult onset neurodegenerative disorder 
causing degeneration of motor neurons in the brain stem, spinal cord, and cerebral cortex. The 
muscle denervation leads to impairment of the neuromuscular system, resulting in paralysis and 
death for respiratory failure within 2–3 years after symptom onset. The majority of ALS cases are 
sporadic, while about 10% are inherited; however, the two forms are clinically and pathologically 
indistinguishable. A limited number of genes, including SOD1, TARDBP, FUS, C9orf72, and TBK1, 
are responsible for a significant proportion of familial and sporadic ALS cases (1, 2). So far, mice 
overexpressing a transgene of human cytosolic superoxide dismutase Cu, Zn dependent (SOD1) 
with ALS-associated mutations are the animal models that most closely mimics the pathological 
phenotype of both familial and sporadic ALS (3). The transgenic mouse carrying the hSOD1G93A 
mutation (SOD1G93A), developed more than 20 years ago, has been widely used to unravel the cascade 
of molecular mechanisms underlying the pathogenesis and progression of ALS (4). These mice 
develop the disease in adulthood, with progressive muscle wasting and paralysis until death, which 
is normally induced by euthanasia when they are unable to right themselves within 10 s after being 
placed on their side. In both mouse models and ALS patients, the denervation of neuromuscular 
junctions (NMJs) and the axonal retraction occur long before the loss of MN cell bodies in the 
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spinal cord and before the symptoms of neuromuscolar deficit 
become evident (3, 5–8). It is likely that initially the axons that 
are still intact can generate compensatory collateral sprouting in 
order to maintain functional muscle activity, but later, when this 
compensatory mechanism fails and the motor neuron degenera-
tion progresses, there is an irreversible muscular atrophy (9).
An intrinsic mechanism at the level of motor neuron cell 
bodies and axon contributes to the pathogenesis of ALS through 
multiple signaling pathways that have been extensively reviewed 
(4, 10, 11). However, accumulating evidence indicate that ALS is 
a non-cell autonomous disease influenced by sustained astroglio-
sis, with microglial activation and blood-derived immune cells 
infiltration in the spinal cord that may have critical functions 
during the disease course (12, 13).
A number of comprehensive overviews have been published 
on the contribution of the innate and adaptive immune system 
in ALS pathology; so, this review focuses on the mechanisms of 
cross-talk between degenerating motor neurons and the adaptive 
immune cells, particularly on the role of the major histocompat-
ibility complex I (MHCI).
MHCi iN THe CNS
An intriguing hypothesis suggests that the evolution of the adap-
tive immune system may have coincided with elaboration of the 
neural crest and tissues derived from it, such as the jaws, at the 
time of increasing complexity of the nervous system (14, 15). In 
these terms, the adaptive immune system may be an evolutionary 
offshoot of the vertebrate nervous system (14, 15). This notion is 
fostered by several genomics studies indicating that the adaptive 
immune system-related signaling genes were ancestrally involved 
in the development and/or function of the nervous system 
(14,  15). In this scenario, it is hardly surprisingly therefore to 
see how specialized immune cells – T cells, B cells, and dendritic 
cells – have evolved an immunological synapse structurally and 
functionally reminiscent of the neural synapse (16, 17).
One of the main factors in the adaptive immune system is 
the MHCI, classically involved in the presentation of peptides 
derived from proteolysis mediated by the immunoprotea-
some (IP) to cytotoxic lymphocytes (18). MHCI belongs to 
the ever-increasing class of immune proteins (e.g., cadherins; 
Thy-1; calcineurin; NF-κB, CD22) later detected in the nervous 
system (19), suggesting that the two compartments share com-
mon signal transduction mechanisms. However, some of these 
molecules, while maintaining the same structure, may also have 
a different function depending on the context in which they act: 
a feature termed pleiotropy (20). In the past decade, studies on 
MHCI activity in the CNS have mainly aimed at demonstrating 
its role in brain development and plasticity, a topic that has been 
amply reviewed (21–23). Instead, less information is available 
about its role in adults. Under normal conditions, the MHCI 
is weakly or even not expressed in mature neuronal cells, but 
its expression dramatically increases after viral or parasitic 
infection (24–26), exposure to cytokines (27–31), and pharma-
cological manipulation of electrical activity (32). In addition, 
MHCI becomes activated in neurons targeted to progressive 
degeneration (33).
Motor neurons seem to be the most responsive in triggering 
the MHCI during normal aging (34, 35), after insults such as 
the axotomy (36) or ventral horn root avulsion (37) or during 
chronic diseases such as experimental autoimmune encephalo-
myelitis in mice (38). We recently reported that spinal motor 
neurons of transgenic mice carrying the mutant SOD1G93A 
markedly activated the expression of several molecules associ-
ated with MHCI at the onset and during the progression of the 
disease (39–41). The mechanism triggering this response and its 
local consequences are not clearly defined yet. However, these 
findings open a new scenario in the pathophysiology of ALS as 
regards cross-talk between the peripheral immune system and 
CNS, which may be aimed either at preventing or exacerbating 
the motor neuron loss. It remains to be seen whether the expres-
sion of MHCI by MNs is closely related to direct communica-
tion with infiltrating immune cells (CD8+ T cells) or whether 
alternative mechanisms can influence motor neuron viability in 
an immune system-independent manner. In this review, we will 
comment on both these possibilities trying to define a potential 
role of MHCI in ALS.
THe NATURe AND GeNeTiCS OF MHCi
Major histocompatibility complex class I molecules are trimeric 
complexes assembled in the endoplasmic reticulum (ER). It 
consists of two non-covalently linked polypeptide chains, known 
as α-chain (divided into three domains: α1, α2, and α3) and beta 
2 microglobulin (β2m) chains that can bind a large set of antigenic 
peptide fragments (8–11 amino acids) produced in the cytosol 
by the IP and translocated into the ER through the transporter 
associated with antigen presentation (TAP) (18). The MHCI is 
then transferred to a vesicle that fuses with the plasma membrane 
to present the peptide fragment extracellularly to CD8+ T lym-
phocytes. These cells recognize MHCI through the CD8 receptor 
and the antigenic peptide trough the T cell receptor (TCR).
The composition of the MHCI-associated antigen peptides 
varies from one cell type to another and can be perturbed by cell-
intrinsic and -extrinsic factors including altered cell metabolism 
and infection (42). Once CD8+ T lymphocytes recognize the 
peptides as non-self or neo-self-antigens, they activate the IP 
and kill the presenting cells directly through the Fas or perforin 
pathways and/or indirectly by the release of cytokines (18, 42) 
(Figure 1). Classical MHCI alpha chains (class Ia) are encoded 
by three genes in both human (HLA-A, -B, and -C) and mice 
(H2-K, -D, and -L) located in the MHC locus on chromosomes 
(chr) 6 and 17, respectively. The gene for β2m is located on a dif-
ferent chromosome (chr 15 in humans and chr 2 in mice) (43) 
(Figure 2).
The MHC region is the most polymorphic of the entire human 
genome (43). Each HLA locus is present in multiple variants 
(alleles) that characterize the individual haplotype according to 
a numerical designation (e.g., HLA-A2, HLA-B5); in mice, each 
haplotype is identified by a letter (e.g., H-2Kd, H-2Dk).
Gene alterations in the MHC class I region have been linked 
to various disorders with neurological symptoms, including 
spinocerebellar ataxia, Huntington’s disease, Parkinson’s disease, 
multiple sclerosis, narcolepsy, dyslexia, schizophrenia, and autism 
FiGURe 1 | Antigen processing through MHC i molecules. MHCI is a tripartite complex that is composed of a non-covalent association of heavy chain (blue) 
with β2m (red). The third component is represented by a short peptide of 8–10 aa (orange), which is processed by the proteasome and translocated to the 
endoplasmic reticulum (ER) lumen through Tap protein (TAP1; TAP2; yellow) where it is loaded onto the MHC complex through the tapasin (Tsn; yellow). After 
loading, MHCI dissociates from TAP/Tsn and traffics to the cell surface along the secretory pathway, where it is monitored by cytotoxic CD8+ T cells. Normally, the 
exposure of a self-peptide on the cell membrane avoids the activation of an immune response. Conversely, the exposure of a non-self-peptide (red) induces the 
activation of an immune response by CD8+ T cells with induction of the immunoproteaseome in which three catalytic proteasome β subunits are replaced by three 
immunosubunits (Lmp7, Lmp2, and Lmp10).
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(44–47). This is a product of the role of MHC class I in adaptive 
immunity, as well as its extraordinary genetic diversity.
A high frequency of the HLA-A3 and HLA-B12 antigens was ini-
tially found to be associated with ALS patients with rapid and slow 
disease progression, respectively. However, this was not validated 
in a subsequent study comparing the HLA antigenic frequency in 
ALS patients and control groups (47, 48). Both studies were made 
on small cohorts of patients and limited to specific geographical 
FiGURe 2 | Genomic map of the human and mouse MHC class i region. A simplified diagram of the human and mouse MHCI genomic regions shows the 
MHC spanning approximately 3.6 Mb, located on chromosome 6 in humans and 17 in mice. The classical MHCI genes (blue) are highly polymorphic. Class II and III 
genes are indicated by white and dashed lines but are not annotated here. The light chain of MHCI molecules, β2m, is encoded on a separate chromosome (15 in 
humans and 2 in mice). Classical MHC class I genes include HLA-A, HLA-B, and HLA-C in humans and H2-K, -D, and -L in mice. H2-L is closely related to H2-D 
and appears to be present only in the BALB/c mouse strain. The two TAP genes (Tap1 and Tap2; yellow) lie in the MHC class II region close to the 
immunoproteasome genes (Lmp2 and Lmp7); yellow in both humans and mice. The gene for tapasin (Tapbp) lies at the edge of the MHC locus nearest the 
centromere. The general arrangement of the MHC is similar in humans and rodents, the main difference being that MHCI genes in mice have become separated at 
both ends of the MHC by class II and III genes.
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areas; so, further analysis is necessary to gain an objective view of 
the genetic association between the MHCI locus and ALS.
The MHC locus is also extremely polygenic as it includes MHC 
class Ia genes, MHCII class Ia genes, and non-classical genes for 
both MCHI and MHCII complexes (class Ib and class IIb) (18, 43). 
In addition, the two TAP genes (Tap1 and Tap2) lie in the MHC 
class II region close to the IP genes (Lmp2 and Lmp7), whereas the 
gene for tapasin (Tapbp), a chaperon protein essential for peptide 
loading, lies at the edge of the MHC locus nearest the centromere 
(Figure 2). The genetic linkage of the MHC class I genes with 
Tap, Tapbp, and Lmp genes suggests that the entire MHC region 
has been selected during evolution for antigen processing and 
presentation (18). No correlation between genetic variations in 
the sequence of these genes and ALS has been described yet. 
Nevertheless, the genetic variant D76N of β2m is responsible for 
a very rare form of familial systemic amyloidosis (49), whereas 
different genetic variants of the IP component Lmp7 have been 
associated with many diseases, including viral infection, autoim-
mune disease, and malignant tumors (50).
MHCi iN THe CNS AND PNS: 
iMPLiCATiONS FOR THe iMMUNe 
ReSPONSe
CNS is considered to be immunoprivileged in order to pro-
tect the postmitotic neural cells from the entry of pathogens, 
circulating immune cells, and other potentially damaging 
factors that may cause the neuronal injury and death. This is 
made possible by the presence of a physical blood–brain barrier 
(BBB) maintained by tight junctions between brain endothelial 
cells, the basal lamina of these cells, and astrocyte end-feet 
processes. In addition, cells in the CNS display very little or 
no expression of immune molecules, such as the MHCI, thus 
avoiding attack by immunocompetent cells and this contributes 
to the immunoprivileged status (51). In pathological conditions 
(viral infection, neuroinflammation, or neurodegeneration), 
a leakage in the BBB has been reported even before the overt 
neurodegeneration together with the neuronal upregulation of 
MHCI, as seen in human postmortem tissues (33, 51, 52). For 
example, both MHCI and β2m are strongly expressed by cortical 
and hippocampal neurons in Rasmussen’s encephalitis, a child-
hood disease causing chronic inflammation of the brain with 
infiltration of T cells in the parenchyma (53). The same occurs in 
dysmorphic/dysphasic cortical neurons of focal cortical dyspla-
sia, tuberous sclerosis complex, and ganglioglioma cases (54), all 
diseases caused by infantile tauopathies. In neurodegenerative 
diseases of adulthood like Parkinson disease, both MHCI and 
β2m were upregulated by dopaminergic neurons in the substantia 
nigra and in norepinephrinergic neurons of the locus coeruleus 
in postmortem tissues (33).
More evidence is available on the neuronal expression of MHCI 
in in vitro and in vivo models under inflammatory stimuli such 
FiGURe 3 | MHCi and LMP7 are strongly activated in primary motor neurons by iNFγ. (A–D) Confocal micrographs, at different magnifications, showing 
marked activation of MHCI (green) and LMP7 (red) by primary motor neurons (SMI-32; blue) of (B) C57 Ntg and (D) C57SOD1G93A mice after exposure to INFγ 
(50 U/ml) for 24 h; scale bar: 50 μm.
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as cytokines or viral infection (52). For example, the rat primary 
motor neurons express high levels of both MHCI heavy chain and 
β2m mRNAs after stimulation for 24, 48, and 72 h, with IFN-γ, 
which is normally produced by activated T-cells and natural killer 
(NK) cells in  vivo (55). Similarly, cultured primary catechola-
minergic neurons expressed high levels of MHCI upon exposure 
for 72 h to IFN-γ, microglial medium prestimulated by LPS or 
exposure to high levels of l-dihydroxyphenylalanine (l-DOPA) 
(33). We also observed that INFγ exposure for 24 h, dramatically 
induced the expression of MHCI and LMP7 in primary spinal 
motor neurons of both non-transgenic and C57SOD1G93A mice 
cocultured with non-transgenic primary cortical astrocytes, and 
the two proteins colocalize in both somata and motor axons 
(Figures 3A–D).
Strong upregulation of MHCI and related molecules 
was also seen in the CNS of mice infected with neurotropic 
viruses. Redwine et  al. (26) showed that infection with a 
strain of murine hepatitis virus induced the transcription of 
MHCI mRNA by oligodendrocytes, neurons, microglia, and 
endothelia. Since the virus causes a chronic, inflammatory 
demyelinating disease, it was suggested that the MHCI activa-
tion in neurons was related to classical direct neuron antigen-
specific interactions with CD8+ T cells leading to damage to the 
neurons. Studies in vitro on primary mouse neurons infected 
by neurotropic Borna disease virus (BDV) or pulsed by 
lympho-choriomeningitis virus envelope glycoprotein (GP33) 
confirmed this indicating that activated CD8+ T cells establish 
stable contacts with axons in an antigen- and MHCI-dependent 
manner (56–58). These stable Fas (neuronal cells)–FasL (CD8+ 
T cells) contacts rapidly cause segmental damage of neurites 
in the form of spheroids or beads, independent of detectable 
morphological changes to the somata (57). Notably, Sauer et al. 
(59) reported that sustained exposure of primary mouse corti-
cal neurons to IFNγ for 72 h was sufficient to upregulate the 
axolemmal expression of MHCI H-2Kb molecules competent 
to present exogenously or endogenously derived SIINFEKL 
(chicken ovalbumin) peptides. They discovered that cytotoxic 
T cells isolated from C57BL/6-Tg(TcraTcrb)1100Mjb/J (OT-I) 
mice and that express a transgenic TCR engineered to recog-
nize H-2Kb-presenting SIINFEKL peptide, formed cytotoxic 
immune synapses with and injured MHCI-expressing axons, 
and mediated axon injury through a MHCI and granzyme 
B-dependent mechanism.
Although the precise mechanism by which CD8+ T cells 
damage neurons calls for further investigation, these data sug-
gest that, if appropriately stimulated, neuronal cells can activate 
MHCI signaling as a means of communication with cytotoxic 
T cells.
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MHCi iN THe CNS AND PNS: THe 
PLeiOTROPiC ROLe
In the past 10 years, the use of animal models has enables us to 
identify an additional non-immunological function for MHCI 
in CNS neurons, strictly related to synaptic remodeling and 
plasticity. More specifically, the lack of a functional MHCI in 
mice profoundly affects synaptic density and transmission of 
neuronal cells in hippocampus, visual cortex, and cerebellum 
during normal development (22). From these studies, it emerges 
that MHCI is required for the establishment of appropriate 
connections between neurons. This activity is apparently 
immune independent and specifically related to the regulation of 
long-term plasticity of excitatory synaptic transmission. It now 
appears that MHCI molecules normally inhibit NMDA receptor 
(NMDAR) function and regulate trafficking of AMPARs after 
NMDAR stimulation (60). Lee et al. (61) clearly demonstrated 
that MHCI induces functional and structural synapse pruning 
during development, balancing the Ca+ influx mediated-long 
terminal potentiation (LTP) in favor of a long terminal depres-
sion (LTD) between CNS neurons. The pleiotropic role MHCI 
was further investigated in adult mice after a mechanical insult 
or trauma. These studies produced controversial results about the 
specific role of MHCI in CNS.
Escande-Beillard et  al. (62) showed that the addition of 
picomolar amounts of recombinant MHCI to cultures of wild-
type neurons could inhibit neurite outgrowth while transgenic 
C57Bl/6 mice engineered to express higher levels of self-Db 
(MHCIa) in their CNS neurons had alterations in hippocampal 
morphology and retinogeniculate projections, as well as impaired 
neurorepair responses to CNS insult (63). In keeping with this, 
the absence of MHCI enhanced neuroprotection after stroke (64). 
Stroke induced in mice lacking these proteins has smaller infarcts, 
larger corticospinal axonal projections, fewer reactive astrocytes, 
and lesser neuronal death supporting the conclusion that MHCI 
signaling contributes to brain injury after ischemia. Thus, the 
significant rises in MHCI components after stroke might reduce 
axonal outgrowth and synaptic plasticity of surviving neurons 
and circuits, limiting functional recovery.
In contrast, other studies show that MHCI is necessary to 
preserve the physiological activity of injured motor neurons in 
the spinal cord, enhancing the recovery of motor function follow-
ing a mechanical insult. For example, Oliveira et al. (37) reported 
that the lack of a functional MHCI in β2m−/− mice subjected 
to axonal transection strongly influenced synapse density and 
axonal regeneration of spinal motor neurons. In β2m−/− mice, 
the synaptic detachments of the soma of lumbar motor neurons 
1 week after peripheral sciatic nerve transection were more exten-
sive than in wild-type animals. This surplus removal selectively 
involved the clusters of inhibitory synapses without affecting 
the loss of excitatory synapses, which remained the same in 
normal and β2m−/− mice. Thus, after axon lesion motor neurons 
preferentially remove excitatory inputs, maintaining a subset of 
inhibitory inputs on the cell and this last effect is strictly depend-
ent on the presence of MHCI. In the same study, Oliveira et al. 
(37) found that fewer motor neurons were able to regenerate new 
axons in the distal nerve stump after axotomy in β2m−/− mice than 
wild-type mice, suggesting a positive effect of MHCI in axonal 
regeneration.
This was subsequently confirmed by studies showing that 
wild-type mouse strains with greater ability to upregulate neu-
ronal MHCI expression after injury had more effective axonal 
regrowth (65). In addition, transgenic mice with enhanced neu-
ronal MHCI expression (NSE-Db) recovered locomotor function 
better after spinal cord injury than wild-type mice (66). On the 
basis of these observations, Thams et al. (36) extensively analyzed 
MHCI expression and distribution in mice subjected to axotomy. 
Surprisingly, despite high levels of mRNA expression, MHCI was 
barely detectable in the motor neurons cell bodies of intact and 
lesioned motor neurons, although there was a marked increase 
in immunoreactivity for MHCI in the surrounding microglia. 
Interestingly, when the peripheral nerve compartment of motor 
neurons was analyzed, marked MHCI immunoreactivity was 
found at the level of putative motor axons of transected sciatic 
nerve and in the NMJs of gastrocnemius muscles.
Thams et al. (36) also reported that mice defective in H2-K 
and H2-D genes (Kb−/−; Db−/− mice) had an abnormal pattern of 
innervation of the hind limb muscles and diaphragm compared 
with wild-type mice. There was a higher density of acetyl choline 
receptor (AChR) clusters, disruption of synaptic band structure, 
and fewer terminal Schwann cells (SCs). These events, which 
profoundly affect axonal regeneration and muscle reinnervation, 
are probably responsible for the delayed improvement in grip 
strength of Kb−/− Db−/− versus wild-type mice after sciatic nerve 
crush (36). These results suggested that, under stress conditions, 
MHCI molecules as soon as they are synthesized are antero-
gradely transported in the axon, an event described also for the 
vomeronasal system in vivo (67) and cortical and hippocampal 
neurons in  vitro (58, 68). However, it cannot be excluded that 
MHCI mRNA is transported to the site of injury where it is locally 
translated (69).
These observations suggest that MHCI plays a role in regulat-
ing the density of NMJs during muscle reinnervation. This effect 
might be due to the inhibition of excessive formation or elimina-
tion of inappropriate NMJs during reinnervation. However, the 
molecular mechanisms of this activity are far from clear, and 
further studies are necessary to establish the specific role of 
MHCI in the periphery.
MHCi iN ALS: iMPLiCATiONS FOR THe 
ADAPTive iMMUNe ReSPONSe
In addition to glial cell activation, a hallmark in the CNS of both 
ALS patients and animal models is the infiltration of blood-
derived immune cells (12, 70, 71). This suggests that ALS is 
characterized by the loss of the immune surveillance typical of the 
healthy CNS. In fact, altered BBB and spinal cord blood barrier 
(SCBB) have emerged from the human pathology and various 
experimental observations in animal models of the disease (72, 
73). A relevant role of T cells in the disease process in ALS has 
been suggested on the basis of marked infiltration of CD8+ 
T cytotoxic and CD4+ T helper lymphocytes in the ventral horn 
of the spinal cord of ALS patients (70, 74). This is corroborated 
by abnormalities in T lymphocytes and NK cells in blood of ALS 
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patients (75–78), although there are differences among studies 
that may be explained by the heterogeneity of the ALS cohorts 
and the limited numbers of patients examined. In ALS animal 
models too, a progressive and massive increase of the CD8+ T 
and CD4+ T cells in the spinal cord has been reported (79, 80). 
Although CD4+ T cells are likely to play a crucial protective role 
in disease by supporting glia-mediated neuroprotection and slow 
disease progression in experimental ALS (12, 77, 81), CD8+ T 
lymphocytes may be directly involved in ALS pathogenesis, as 
recently proposed by Bowerman et al. (82). Cytotoxic T lympho-
cytes may affect motor neuron survival in different ways. The first 
involves the Fas ligand protein expressed on the surface of the 
CD8+ T cells interacting with the Fas receptor expressed by the 
target cells, which triggers apoptosis through the classical caspase 
cascade (83). Fas receptor is highly expressed by motor neurons 
expressing the ALS-linked SOD1 mutation in vivo and Fas induc-
tion by administration of exogenous NO (detanonoate) for 48 h 
triggers a death pathway in cultured mSOD1 motor neurons (84, 
85). On the other hand, upon recognition of the motor neuron 
by CD8+ T cells, cytotoxic granules containing perforin and 
granzyme may be released into the extracellular space. Perforin 
is a pore-forming protein that might allow entry into the target 
cells of granzyme serine proteases that induce caspase activation 
and cell death (83). Thus, this suggests that CD8+ T cells have a 
direct neurotoxic effect on motor neurons in ALS. How this may 
happen?
We recently reported that the motor neurons of C57SOD1G93A 
mice at the disease onset markedly upregulate the expression 
of MHCI, which accumulate preferentially in motor axons and 
NMJs [Ref. (41) and Figures 4A–DI]. In concomitance with this 
response, there was an upregulation of the IP subunits in the 
C57SOD1G93A motor neurons, particularly Lmp7, suggesting that 
motor neurons locally produce and expose to the environment an 
MHCI complex “loaded” with autoantigenic peptides (41). The 
intense immunolabeling of MHCI protein in the sciatic nerve of 
SOD1G93A mice indicates a potential direct interaction between 
motor axons exposing autoantigenic peptide and infiltrating 
cytotoxic T cells at this level.
The peripheral interaction of motor neurons with cytotoxic 
CD8+ T cells may therefore be the direct cause of motor axon 
injury in SOD1G93A mice; however, how the MHCI is triggered 
in ALS motor neuron is not known. A possible explanation lies 
in the proteinopathy and neuroinflammation typical of this 
disease (39). The accumulation of misfolded proteins in the 
motor neurons due to genetic mutations or their oxidation is 
not only one of the main neuropathological hallmarks of ALS 
but probably also the primum movens in the cascade leading 
to motor neuron degeneration. The misfolded proteins, which 
cannot be properly degraded by the constitutive proteasome or 
other protein quality control systems, can be directed toward the 
INFγ activated IP (39). At the same time, the misfolded proteins 
in the motor neurons may trigger the inflammation through 
the release of danger-associated molecular pattern molecules 
(DAMPs), including ROS, HMGB1, and HSPs, which activate 
glial and immune cells to produce inflammatory cytokines 
including IFNγ (86, 87). IFNγ may then induce upregulation 
of the IP in the motor neurons, and other cells leading to the 
overproduction of neuronal and glial antigens presented on 
MHCI molecules. In primary cocoltures of astrocytes and 
spinal neurons from transgenic SOD1G93A or non-transgenic 
mice, the addition of INFγ to the medium for 24 h markedly 
induce the expression of MHCI and LMP7 in motor neurons 
and the two proteins colocalize in both somata and motor 
axons (Figures  3A–D). No differences were observed in the 
basal expression of MHCI and LMP7 between SOD1G93A and 
non-transgenic MNs. This indicates that the only presence of 
mutant SOD1, even if misfolded, is not sufficient to trigger the 
activation of MHCI cascade in the motor neurons. Since INFγ 
is secreted by activated microglia and CD8+ T cells, the presence 
of these cells in vivo may be a prerequisite to activate the MHCI 
cascade in SOD1G93A motor neurons triggering the cascade lead-
ing to their death. Although the activation of resident microglia 
may result from the release of DAMPs in the extracellular 
space around motor neurons, the recruitment of CD8+ T is 
probably a consequence of a disruption of the BBB, which has 
been reported in ALS patients and mouse models of the disease 
(72, 73). This scenario suggests the involvement of autoimmun-
ity as a potential pathogenic mechanism of ALS (88). In fact, 
large-scale mass spectrometry studies have revealed that the 
repertoire of endogenous peptides that is normally presented 
by MHCI to CD8+ T cells (self-MHCI peptides) is more com-
plex and plastic than previously anticipated. Its composition 
varies from one cell type to another and can be perturbed by 
cell-intrinsic and -extrinsic factors including dysregulation of 
cellular metabolism and infection (42). Accordingly, the pro-
inflammatory environment of spinal cord and the dysregulated 
protein metabolism of motor neurons during ALS may promote 
the activation of the IP and the exposure, on the cell membrane, 
of antigenic peptides recognized as non-self by CD8+ T cells, 
which then activate a cytotoxic autoimmune response.
That said, the contribution of cytotoxic T cells to the patho-
physiology of ALS certainly calls for deeper investigations.
However, recent observations do not support the detrimental 
role of MHCI activation in ALS motor neurons, but rather sug-
gest a protective effect. For example, the MHCI cascade is only 
barely activated in the motor neurons of 129SvSOD1G93A mice, 
which have more aggressive disease course and shorter lifespan 
than C57SOD1G93A mice, although they overexpress the same 
amount of the mutant SOD1 transgene and show similar loss 
of lumbar spinal cord motor neurons perikarya (41, 89). The 
difference in disease severities is probably related to a functional 
impairment of the motor neurons at the axonal level, as dem-
onstrated by the marked swelling and vacuolation of myelinated 
axons observed in the ventral spinal cord of the fast-progressing 
129SvSOD1G93A mice at the presymptomatic stage, while this 
was seen later in the slow progressors C57SOD1G93A mice (89). 
In addition, earlier abnormalities were seen in the axonal com-
partment of 129SvSOD1G93A mice by ex vivo diffusion tensor 
imaging and histological analysis of the white matter of the spi-
nal cord (90). Axial diffusion was reduced in the ventro-lateral 
and  -dorsal white matter of 129SvSOD1G93A mice compared 
with the non-transgenic littermates already at the onset of the 
disease, while in C57SOD1G93A mice, this appeared only at the 
advanced stage (90).
FiGURe 4 | MHCi activation and CD8+ T cell infiltration in the neuromuscular system of SOD1G93A mice at disease onset. (A,B) Confocal micrographs of 
the sciatic nerve of C57SOD1G93A mice at disease onset showing remarked upregulation of MHCI (green) and colocalization with Smi31 (axonal marker; red) in 
pathological conditions. (C,Di) Confocal micrographs from tibialis anterior muscle of (C) Ntg and (D) C57-G93A mice showing accumulation of MHCI at the NMJ 
under pathological conditions (BTX; α-bungarotoxin; postsynaptic marker). (Di) 3D rendering of (B) from the same angulation (Volocity – Perkin Elmer). (e–G) 
Confocal micrographs showing the presence cytototoxic T cells (CD8, green) in the tibialis anterior muscle of C57-G93A mice in proximity to NMJs, indicated by 
yellow arrows.
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These data suggest that the activation of MHCI in motor 
neurons of C57SOD1G93A mice at the onset of the disease may 
be predictive of better preservation of axonal function, with a 
positive impact on the disease progression (41). This hypothesis 
was recently strengthened by Staats et al. (91) who reported that 
the ubiquitous removal of β2m in SOD1G93A mice shortened the 
disease duration by anticipating their death.
As previously shown, MHCI is mainly expressed by motor 
axons in the periphery of C57SOD1G93A mice (41), so there may 
be a privileged interaction between motor neurons and CD8+ 
T cells at this level and not in the spinal cord. The activity of the 
immune system in the PNS of mSOD1 mice has hardly been 
considered in ALS, but there is mounting evidence that the 
contribution of the inflammatory response in the PNS stands 
in stark contrast with that of the CNS, where the activity of 
nearby cells (microglia, astrocytes, and infiltrating immune 
cells) exacerbate cell death and damage by releasing toxic pro-
inflammatory mediators over a long period of time. Successful 
axonal regeneration depends on the coordinated effort of non-
neuronal cells that, while removing motor axon debris, release 
extracellular matrix molecules, cytokines, and growth factors 
that support axon regrowth (92). New evidence indicates that 
innate and adaptive immune responses can facilitate CNS repair 
at a later stage by restricting a prominent secondary wave of 
damage in multiple sclerosis and other disorders (93, 94). For 
example, autoimmune T cells that are specific for the myelin 
basic protein (MBP) protect CNS neurons from secondary 
degeneration possibly through antigen-mediated production of 
nerve growth factors into the environment (95). In vivo imaging 
in a mouse ALS model indicated distinct inflammatory activity 
of CNS microglia compared with PNS macrophages, the latter 
lacking any substantial morphological reaction during degen-
eration of peripheral motor axons, but a passive role in clearing 
debris, particularly lipid-rich myelin (96). This is in line with 
Chiu et al. (79) who reported an increase in CCL2 expression 
and intense deposits of complement C3 throughout the paren-
chyma of the sciatic nerve of SOD1G93A mice which resulted 
in progressive macrophage infiltration without the activation 
of classical pro-inflammatory factors such as TNFα and IL-6. 
CCL2-mediated neuron–macrophage interaction is critical for 
amplification and maintenance of enhanced regenerative capac-
ity by preconditioning peripheral nerve injury (97). In addition, 
Barrette et  al. (98) found that peripheral macrophages were 
essential to promote the production of neurotrophins within 
the regenerating PNS since macrophage depletion significantly 
slowed axon regeneration and functional recovery after sciatic 
nerve injury. At the same time, the CCL2-mediated neuron–
macrophage interaction is critical for amplification and main-
tenance of enhanced regenerative capacity by preconditioning 
peripheral nerve injury (97).
Finally, in keeping with the presence of MHCI at the NMJ 
of C57SOD1G93A mice, we found T cell infiltrated in close 
proximity to motor end plates in the tibialis anterior muscles of 
C57SOD1G93A at the disease onset (Figures 4E–G). Therefore, we 
cannot exclude an interaction between infiltrating T cells and 
autoantigens, exposed by MHCI on degenerating NMJs, actively 
influencing synaptic refinement and plasticity. At this same 
level, CD8+ T cells may act in concert with activated peripheral 
 macrophages recruited within bundles of innervating axon 
tracts of tibialis anterior muscles of SOD1G93A mice at disease 
onset (79). This suggests that the activity of immune cells may 
be essential in the degradation of defective terminals in order 
to facilitate more efficient collateral reinnervation by surviving 
motor neurons during the first phases of the disease. This is con-
sistent with denervation and reinnervation changes observed in 
the fALS animal model and ALS patients during the progression 
of the disease (7).
MHCi iN ALS: THe  
NON-iMMUNOLOGiCAL ROLe
As discussed previously, MHCI has been firmly implicated 
in neuronal plasticity, regulating synaptic density and axonal 
regeneration in the CNS and PNS during development and in 
brain diseases (22, 33). The mechanisms governing these effects 
are unknown, but evidence from different compartments of the 
cerebral cortex indicates the presence of immune-like MHCI 
receptors in the CNS (22, 23, 52). In fact, although there is no 
evidence of TCRα and TCRβ expression, CD3ζ is found through-
out the CNS and CD3ϵ is expressed in the cerebellum (22). At 
the same time, NK receptors, such as PirB and Ly49, have been 
observed in axonal growth cone and synapses of hippocampal 
neurons in vivo and cortical neuron in vitro (22). Animal models 
defective in PirB, CD3ζ, or CD3ϵ show neurological defects simi-
lar to those in MHCI-KO mice models, so an interaction of these 
receptors with MHCI is possible, although not directly proven 
(22, 52). In the brain, MHCI protein is expressed by neurons, 
especially on the surface of axons and dendrites (32) as well as 
both pre- and postsynaptically (99, 100). However, it is almost 
undetectable in spinal motor neurons soma of axotomized and 
SOD1G93A mice, but marked accumulation has been seen in motor 
axons and NMJs (36, 41). Given this MHCI protein expression in 
the periphery, SCs expressing PirB on their surface may be their 
counterpart at this level (36, 101). This finding provides a basis 
for possible MHCI-mediated signaling between motor neuron 
and SCs in the sciatic nerve involved in motor axon homeostasis 
and stability.
In the PNS, SCs are the main source of paracrine support to 
motor axons forming close bidirectional relationship with their 
neuronal partners. During development, the SCs are essential for 
the survival of motor neurons, while the neuron-derived factors 
are essential for the survival and differentiation of SCs along 
axons (102). These interactions are also important when there is 
peripheral damage to preserve the myelin sheath around motor 
axons. SCs, with macrophages, phagocize their myelin sheaths 
and then SCs enter a de-differentiation/proliferation program 
to support the motor axon by remyelinating it (103, 104). Early 
morphological, biochemical, and molecular alterations have 
been observed in SCs from sciatic nerve of SOD1G93A mice 
(5, 105–107), suggesting that these cells are dysregulated during 
the development of ALS. Therefore, in the sciatic nerve, MHCI 
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FiGURe 5 | Schematic diagram of the potential mechanism of action of MHCi-associated molecules in the motor neuron of a mutant SOD1 mouse 
model of ALS.  
 (Continued)
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may potentiate the proliferative activity of SCs during disease 
progression to promote long-lasting preservation of motor axons. 
At the same time, the high expression of MHCI at the NMJs may 
be responsible for the activity of terminal SCs, since the removal of 
MHCI has a dramatic effect on their proliferation (36). Terminal 
SCs provide stability, produce growth factors, and are involved 
in synapse homeostasis (108–110). In addition, they are essential 
for the removal of inappropriate presynaptic terminals during 
reinnervation (111, 112).
Major histocompatibility complex I negatively regulates 
the initial establishment of connections and promotes the 
elimination of inappropriate synapses in hippocampal and 
cortical neurons (22). This process is mediated by MHCI also 
in the NMJs (35). Both developmental synapse elimination and 
aging-related synapse loss are promoted by MHCI. The reduc-
tion of MHCI in the NMJs induces the formation multiply 
innervated muscle fibers, suggesting that MHCI is essential for 
the postsynaptic site transition from dual- to monoinnervation. 
All muscles, during development, undergo a transient period of 
poly-innervation, receiving as many as 12 distinct inputs from 
different MNs in the spinal cord at birth (110, 113). These ini-
tially superabundant inputs are removed in a protracted process 
called synapse elimination until each muscle fiber receives input 
from a single MN.
The muscle reinnervation after a nerve lesion or during 
the progression of ALS undergoes the same processes of poly-
innervation, pruning, and refinement as in normal development 
(69, 114). Signals promoting axonal growth and branching are 
activated during this phase. At the same time, growth control 
mechanisms are turned on to consolidate connection patterns 
and confine plastic phenomena to specific sites (69). MHCI 
signaling probably belongs to this second class of mechanisms 
acting to fine regulate and accelerate collateral reinnervation and 
sprouting, as a compensatory response to the progressive motor 
neuron injury ALS. Work on this hypothesis may provide clues on 
how to develop strategies for increasing the muscle reinnervation 
and delay the disease progression.
CONCLUSiON
Over the past 10 years, it has become clear that neuronal MHCI 
molecules play a significant role in the development and plasticity 
of the CNS and PNS in normal and pathological conditions (22, 
33). Here, we report a protective role of MHCI in ALS, as we 
observed specific activation of the MHCI pathway in spinal motor 
neurons of slowly progressing C57SODG93A mice with MHCI 
protein accumulating preferentially in motor axons and NMJs. 
MHCI expression was almost absent in 129SvSOD1G93A mice that 
have a more aggressive disease due to earlier alterations of motor 
axons (41).
Our results support previous findings in axotomized mice, 
indicating that MHCI is fundamental in order to enhance 
locomotor function and accelerate axonal regrowth and muscle 
reinnervation in the PNS. In addition, it was recently observed 
that the ubiquitous removal of β2m in SOD1G93A mice shortened 
the disease duration (91).
Despite the clear importance of MHCI in axonal regrowth 
and in delaying ALS progression, the mechanisms of these effects 
are mostly unknown. Here, we speculate about a potential dual 
activity of neuronal MHCI in the PNS of SOD1G93A mice.
The first involves a direct interaction of motor axons with 
infiltrating CD8+ T cells through possible specific self-antigens 
presented by MHCI in motor neurons. Our in vitro and in vivo 
data testify of concomitant activation of the IP and MHCI in 
mSOD1 motor neurons. In SOD1G93A mice with an accumula-
tion of MHCI in the peripheral nerves and NMJs, this interac-
tion with CD8+ T cells may have a central role in regulating 
the homeostasis of the PNS during disease progression. The 
second involves the activity of MHCI to directly control the 
proliferation of SCs in the sciatic nerve and NMJ, in order to 
preserve the maximal efficiency of motor axon connectivity 
with target muscles. These immune and pleiotropic activities 
of MHCI may be closely connected. It is likely that during the 
course of ALS, the MHCI cascade is activated by motor neu-
rons and transported to the periphery where the recruitment 
of cytotoxic T cells and peripheral macrophages potentiates 
the degradation of defective motor fibers (115) expressing 
axon growth inhibitors (e.g., myelin debris) in an attempt to 
promote the de-differentiation and proliferation of SCs and 
the resulting preservation of motor axons connections with 
muscles (Figures 5A–C).
In the future, it will be crucial to determine what prevailing 
role MHCI has in motor neurons affected by ALS, whether 
protective or harmful. Particularly, evaluating which antigens 
are presented by the damaged MHCI-expressing motor axons 
(A) Cell body. Due to an impairment of constitutive proteasome (CP), the mSOD1 (or other misfolded proteins) is driven to the immunoproteasome (IP), which is 
activated by the INFγ derived from activated resident microglia or from blood-derived CD8+ T cells recruited through the impaired blood spinal cord barrier (BSCB). 
The small antigenic peptides resulting from the IP activity are then loaded onto MHCI and rapidly translocated to the axons. It is likely that the translocation happens 
after the assembly of the MHCI molecule and peptide, although part of it may also occur along the motor axons. (B) Sciatic nerve. The antigenic peptide is 
presented through MHCI by defective motor axons to cytotoxic CD8+ T lymphocytes that infiltrate the sciatic nerve together with peripheral macrophages due to the 
damaged blood nerve barrier (BNB). The concerted removal of defective myelin by dysregulated/autophagocitic SCs, cytotoxic T cells, and macrophages is a 
prerequisite for the de-differentiation/proliferation of SCs (probably promoted by a motor axons–MHCI/SCs–PirB interaction) in order to create a growth-permissive 
milieu for new neurites. (C) Neuromuscular junction. The high expression of MHCI in the motor axon terminals might promote the pruning and collateral reinnervation 
of muscles through two mechanisms such as (i) by presenting antigenic peptides to cytotoxic T cells which, in concert with macrophages, prune the damaged axon 
terminals (motor neuron 1; MN 1) and promote collateral reinnervation (MN 2); (ii) by promoting the proliferation of terminal SCs that produce growth factors, provide 
stability to terminal synapse homeostasis and participate in the removal of inappropriate presynaptic terminals during reinnervation.
FiGURe 5 | Continued
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